Faville, C., E Silva, B., Vilanova Mana, L., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M., Willems, L., & Ehx, G. (18 March 2025). Optimization Of An MHC-I immunoprecipitation Protocol For Mass Spectrometry Analyses Of Persister-Specific Antigens In Acute Myeloid Leukemia [Poster presentation]. EACR Conference "Persister Cells: from Bacteria to Cancer". |
Joris, T., Jouant, T., Jacques, J.-R., Gouverneur, L., Saintmard, X., Vilanova Mana, L., Jamakhani, M., Reichert, M., & Willems, L. (November 2024). Reduction of antisense transcription affects bovine leukemia virus replication and oncogenesis. PLoS Pathogens, 20 (11), 1012659. doi:10.1371/journal.ppat.1012659 |
Willems, M.* , Hamaïdia, M.* , Fontaine, A., Grégoire, M., Halkin, L., Vilanova Mana, L., Terres, R., Jamakhani, M., Deshayes, S., Brostaux, Y., HEINEN, V., LOUIS, R., Duysinx, B., Jean, D., Wasielewski, E., Scherpereel, A., Blanquart, C., & Willems, L. (28 October 2024). The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. EBioMedicine, 109, 105418. doi:10.1016/j.ebiom.2024.105418 * These authors have contributed equally to this work. |
Faville, C., E Silva, B., Cobraiville, G., Ehx, G., Fillet, M., Baron, F., De Voeght, A., Vilanova Mana, L., Willems, L., Baiwir, D., & Mazzucchelli, G. (October 2024). Optimization of an MHC-I immunoprecipitation protocol for mass spectrometry analyses of persister-specific antigens in acute myeloid leukemia [Paper presentation]. yBIS: 1st annual meeting. |
Faville, C., E Silva, B., Vilanova Mana, L., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M., Mazzucchelli, G., Ehx, G., Baiwir, D., & Willems, L. (September 2024). Optimization Of An MHC-I immunoprecipitation Protocol For Mass Spectrometry Analyses Of Persister-Specific Antigens In Acute Myeloid Leukemia [Poster presentation]. GIGA Day. |
Sriramareddy, S. N.* , Jamakhani, M.* , Vilanova Mana, L., Brossel, H., Staumont, B., & Hamaïdia, M. (06 February 2024). Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer. Frontiers in Oncology, 14, 1323313. doi:10.3389/fonc.2024.1323313 * These authors have contributed equally to this work. |